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Abstract: Drug and chemical development along with safety tests rely on the use of numerous clin-
ical models. This is a lengthy process where animal testing is used as a standard for pre-clinical 
trials. However, these models often fail to represent human physiopathology. This may lead to poor 
correlation with results from later human clinical trials. Organ-on-a-Chip (OOAC) systems are en-
gineered microfluidic systems, which recapitulate the physiochemical environment of a specific or-
gan by emulating the perfusion and shear stress cellular tissue undergoes in vivo and could replace 
current animal models. The success of culturing cells and cell-derived tissues within these systems 
is dependent on the scaffold chosen; hence, scaffolds are critical for the success of OOACs in re-
search. A literature review was conducted looking at current OOAC systems to assess the ad-
vantages and disadvantages of different materials and manufacturing techniques used for scaffold 
production; and the alternatives that could be tailored from the macro tissue engineering research 
field.  
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1. Introduction 
Research and development in the pharmaceutical and chemical industries have en-
countered barriers since their conception with regards to the development and selection 
of appropriate pre-clinical test models [1]. Pre-clinical testing relies on animals or animal-
derived models, which are costly, have significant ethical implications and are not accu-
rate representations of human physiopathology [2]. Thus, it is imperative to create acces-
sible animal-free technology and techniques with enhanced predictive power, which al-
low the detection of unsuccessful or toxic candidates in the early stages of research [2].  
Traditional alternative systems to animal models such as 2D/3D cellular cultures are 
simple, low cost and allow reproducible set-up; nevertheless, they still possess inherent 
limitations such as an inability to emulate both organ and system-level functions. Signifi-
cant progress has been made in developing and validating robust/reliable alternative test 
systems. This has been driven by an increasing acceptance of regulators and industry to 
commit to the three Rs of animal usage in research (replacement, reduction and refine-
ment) [3]. 
For the past 25 years, new concepts of micro-engineering models in the early health 
technology assessment (HTA) stage [4] have emerged, similar to the microfabrication of 
versatile microfluidic chips [5]. Organs-on-a-Chip systems (OOAC) are biomimetic sys-
tems with µm-scale fluidic channels that aim to recapitulate the complex physiopathology 
of living human organs by providing a 3D environment susceptible to mechanical, elec-
trical and chemical cues that are key to the architecture and phenotypic changes in tissues 
[6]. Moreover, OOAC presents a highly competitive advantage with homologous 
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technologies since their size generates small samples with high degrees of functionality 
and complexity whilst reducing the need for a large number of reagents or significant 
analysis time [7]. The concept of an integrated Human-on-a-Chip (Figure 1) based on the 
connection of different validated OOACs devices could be used as a potential future al-
ternative to animal models in pre-clinical trials for analysis of drug side-effects and pa-
tient-specific response. This model not only would cut cost and time in pre-clinical testing 
but would also lead to the replacement of animal subjects as a whole in the pharma and 
cosmetic industry [8]. 
 
Figure 1. Human-on-a-Chip Scheme [9–13]. 
The OOAC system consists of a microfluidic chip with chambers and channels where 
cells are seeded into an appropriate matrix or scaffold. The heterotypic culture of cells 
(i.e., the culture of different cell types or different cell subpopulations) in a microfluidic 
chip should, at a simplistic level, be able to emulate the different layers of tissue to repli-
cate the organ’s functionality, vascular system and to provide a structural extracellular 
matrix (ECM). Co-culture systems aim to explore how cells react to different stimuli such 
as chemotaxis and mechanical cues that affect tissue function and molecular pathways 
[14].  
To allow a successful culture of cells in 3D and, consequently, replicate physiological 
tissue architecture, naturally derived and synthetic polymeric scaffolds are included in 
OOAC systems. These scaffolds should be chosen based on the demands of the specific 
cellular tissue since a variety of materials and techniques are used to alter the scaffold 
characteristics [15].  
State-of-art commonly used OOAC scaffolds include poly(dimethylsiloxane)—
PDMS—and MatrigelTM, but both materials pose some challenges in organotypic cultures 
of human cells. The Lung-on-a-Chip system, for example, uses microporous elastomeric 
membranes of PDMS as its flexible properties allow the emulation of the mechanical 
stretch these cells undergo in the lung environment [9]. Nevertheless, this is a non-de-
gradable material that does not contribute to the formation of natural ECM. As an alter-
native, MatrigelTM is an animal-derived gel-like scaffold that contains growth factors and 
hormones, promotes cellular attachment and provides a 3D architecture for tissue for-
mation [15]. However, due to its origin, there is significant batch-to-batch composition 
variability, which affects experimental results reproducibility [16]. These examples show 
how scaffolds currently used within the OOAC research field are still flawed and can lead 
to the failure of these systems as reliable pre-clinical models. 
This paper aims to provide a summary of scaffold requirements, review different 
materials and manufacturing techniques that can be used to produce the optimal scaffold 
according to the OOAC specifications. The paper will analyse the advantages and disad-
vantages of currently used methods and how macro-tissue engineering techniques could 
transcend into the OOAC research field.  
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2. Scaffold Requirements 
The extracellular matrix is a 3D agglomeration of extracellular molecules such as col-
lagen, enzymes and glycoproteins produced by cells, which are responsible for the struc-
tural architecture of in vivo connective tissues. Cell behaviour is modulated by the dy-
namic role of mechanical and spatial signals from the ECM [17].  
The ECM is a molecular network that has proteins, glycosaminoglycan and glycocon-
jugates as its major components [18]. It is responsible for the regulation of cellular migra-
tion, wound healing, cellular anchoring, and the differentiation process. The organisation 
of the ECM consists of the interstitial matrix—an amorphous gel made of collagen, elastin 
and fibronectin—and the basement membrane—denser and less porous than the intersti-
tial matrix, highly organised tissue found in epithelial and endothelial tissues. In tissue 
engineering, the ECM is used as a scaffold and to induce differentiation of MSCs [19].  
When creating an OOAC system, one must consider the type of tissue they aim to 
recapitulate since the scaffolding characteristics will be different. For example, many con-
nective tissues such as articular cartilage and the intervertebral disk have large amounts 
of water and proteoglycans [20]. While, for instance, mammary epithelial tissue ECM pre-
sents large quantities of fibronectin, tenascin, laminin, among other molecules, that largely 
influence cell behaviour [21]. Effective 3D scaffolds need to be porous to allow media per-
fusion and cell proliferation, biocompatible with the specific cell type used and made of 
biodegradable materials thus that cells may replace them with their natural ECM [22,23].  
Creating organ emulating scaffolds is a challenge since many variables must be taken 
into consideration, including biocompatibility, biodegradability, pore size and suitable 
mechanical properties [24]. 
A plethora of biomaterials and manufacturing techniques have been rapidly devel-
oping. However, each biomaterial still presents limitations to achieve optimal scaffolds 
for OOAC systems [25]. 
2.1. Biocompatibility 
When manufacturing a scaffold, biocompatibility must be ensured since cellular tis-
sue has a natural tendency to reject external materials if they fail to provide the specific 
nutritional and biological conditions for cell maintenance [26]. Cell culture requirements 
include temperature, pH, oxygen and carbon dioxide levels, and the use of specific nutri-
tional mediums for the specific cell line. Temperature affects growth and production pro-
cesses, and it ranges between 36–37 °C for most human and mammalian cell lines. The cell 
culture medium must provide a continuous supply of oxygen to the cell through diffusion 
on a liquid surface. A total of 4–10% carbon dioxide is also used on most cell culture ex-
periences since it assists in balancing pH levels as a buffer in the growth medium. The 
majority of mammal cell lines grow at a pH of 7.4, with some fibroblast lines being re-
ported to grow in slightly more basic pH (7.4–7.7) [27,28]. The cell culture medium can be 
naturally derived or artificially manufactured. Natural medium includes biological fluids 
(plasma, serum, etc.), tissue extracts or clots (coagulants or plasma clots) [29]. Artificial 
medium is prepared by adding nutrients such as vitamins, salts, O2 and CO2 gas phases, 
cofactors, among others [30]. The composition of the medium varies according to its pur-
pose, for example, indefinite growth or specialised functions [29]. For the OOAC system 
to be successful, these requirements must still be met thus that the tissue may grow 
healthy and emulate physiological conditions [31]. 
Scaffolds must allow cell adhesion whilst providing a biologically functional envi-
ronment that allows cell migration [24]. The biomaterial utilised must be safe and not in-
duce cytotoxicity. Thus, OOAC systems that house immune system cells must not pro-
voke an inflammatory response or exacerbate immunogenicity [32]. 
Moreover, robust cell adhesion is crucial for the successful cell proliferation process, 
which is divided into three steps—cell attachment, cell spreading and focal adhesion be-
tween cells and the scaffold surface [33]. Cellular differentiation is affected by the 
Bioengineering 2021, 8, x FOR PEER REVIEW 4 of 31 
 
microstructural and physicochemical properties of the scaffold since they impact protein 
adsorption. Thus, altering the surface and topography of the scaffold makes it tunable to 
protein adsorption and cell adhesion according to its function [34].  
With the growing interest in technologies such as microfluidic chips for research, the 
development of biocompatible materials has exponentially increased [35]. 
2.2. Biodegradability 
The main goal of tissue engineering is to provide a structure where cells can grow 
and ultimately replace the scaffold with their own natural ECM. Hence, manufactured 
scaffolds must be biodegradable [24]. The use of synthetic biodegradable polymers has 
been significant in tissue engineering applications since it can improve mechanical prop-
erties for tissue growth. A suitable biodegradability rate must be inversely proportional 
to the production of natural tissue by the cells [36]. Biodegradation kinetics also play a 
role in the release of drugs for tissue manipulation. An example of this can be seen in long-
term therapies where slow degradation kinetics scaffolds such as PLA, PGA and PLGA to 
name a few, are used to perform a controlled drug release [37]. The degradation of the 
manufactured scaffolds results in by-products over time, which cannot be toxic to the cells 
and should be easily flushed out of the scaffold [32]. For example, it has been observed 
that PLA, PGA and their co-polymers to be related to acidic by-products, which affect the 
pH of the environment due to the production of lactic and glycolic acid resultant from the 
hydrolysis of these scaffolds [38,39]. The biodegradation rate of the scaffold is dependent 
on the scaffold’s specifications (composition, microarchitecture and mechanical proper-
ties), abiotic environmental factors (temperature, pH, salinity) and biotic factors (cell type 
cultured, microbiome) [40]. Furthermore, studies have proven that in vivo has an acceler-
ated biodegradation rate when compared with to vitro models due to factors such as lack 
of immune system and hydrolytic/enzymatic properties [41]. Moreover, when comparing 
the degradation rate in static versus microfluidic models, it has been observed that the 
insertion of flow significantly changes the degradation conditions. The flow also produces 
a mechanical load onto the scaffolds and consequent shear stress, which leads to weight 
loss by degradation of the scaffold, further  the flow perfusion increases the surface area 
to degradation. For example, Ma et al. reported the highest porosity in PLGA scaffolds in 
a micro-channel condition when compared with incubator static and incubator shaking 
conditions, with the latest recording 0% porosity between day 21 and day 28, while the 
micro-channel conditioned scaffold maintained porosity at 8%. [42]. There is a gap in re-
search concerning degradation rates in microfluidic devices since many factors can change 
the time a scaffold takes to degrade, such as the type of OOAC model that is being used, 
the physiological function of each cell type [43], the flow rate, different types of reagents 
used in the experiment, porosity and pore size and material chosen. Furthermore, the 
timeline of degradation of a certain scaffold is not comparable to in vivo and static in vitro 
because of the reasons explained beforehand.  
OOAC systems that aim to reproduce the symbiosis between cellular tissue and the 
microbiome, such as the Gut-on-a-Chip must also consider the degradation rate of the 
seeding scaffold when adding different strains of bacteria to emulate the in vivo environ-
ment [44]. Enzymes produced by bacteria have been shown to significantly accelerate the 
catalytic chemical degradation of scaffolds when compared to systems without a micro-
biome present [40]. 
2.3. Mechanical Properties 
Mechanical forces are transduced into biochemical cues that regulate cell communi-
cation, active phenotypical changes, and cellular function accordingly. In vivo tissue bar-
riers are continuously subjected to cyclic mechanical strain [45].  
Scaffolds used in OOAC systems must mimic the conditions of the cellular tissue or 
organ they aim to replicate by maintaining mechanical integrity, thus allowing the proper 
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physiological function of the tissue [46,47]. Moreover, the chemical composition, construct 
and function of the natural in vivo ECM must be replicated [48]. Natural tissues contain 
structural proteins like collagen and fibronectin. These proteins are commonly used to 
functionalise different scaffolds and improve their characteristics [49].  
Mechanical strength is a property critical for a scaffold to be used successfully in cell 
culture [50]. Tests, such as tensile strength, compressive stress and wettability, are com-
monly performed to assess if these properties are within the suitable range. Wettability 
assays give an insight into the scaffold surface roughness and porosity as well as biocom-
patibility [51]. Tensile strength tests allow the study of the scaffold viscoelastic properties 
[25]. As tissues are viscoelastic, they show signs of creep as mechanical forces cause mol-
ecules within the ECM to rearrange; when the force is removed the tissue returns to its 
original shape. Young’s modulus (E) gives an insight into the elasticity of the material; it 
is the ability of the material to undergo a change in length when under either a tensile or 
compressive stress.  
Biomaterial properties change according to manufacturing techniques and condi-
tions of the surrounding environment, thus it is critical to evaluate each scaffold individ-
ually [25]. 
The mechanical properties of the scaffold should be chosen to match those of the tis-
sue that is being formed. The arterial wall has a Young’s modulus of 1 MPa. Researchers 
trying to mimic this in an OOAC use a PDMS scaffold with E = 705 kPa [52]. Lung tissue 
is less stiff and shows E = 3.4 kPa in uniaxial tension [53],therefore, a scaffold with similar 
properties would give optimal emulation of the organ. Previously groups tended to PDMS 
as the scaffold of choice when developing Lung-on-a-Chip models [9]; however, due to its 
high Young’s modulus, hydrogels are becoming more common as they can mimic the 
stiffness of the lung ECM. Huang et al. recently showed a GelMA based scaffold with a 
modulus of 6.23 ± 0.64 kPa [54].  
Cells and tissues within OOAC devices undergo a range of mechanical stimuli, in-
cluding laminar, pulsatile, and interstitial flow along with tensile and compressive forces, 
a good review of methods is written by Kaarj and Yoon [55]. Forces can be applied to 
scaffolds in OOAC devices to actuate tissue structures. These are in the order of µN to 
mN depending on the dimensions of the scaffold. These forces have a significant role in 
tissue development. It has been found that in the basal membrane of the lung, is thinner 
and, therefore, less stiff than the surrounding ECM. These lower stiffness sections are 
where epithelial buds form [56]. Shear stress has been shown to affect the differentiation 
of stem cells [57]. Mechanical stimulation can alter the expression of proteins from cells 
whilst the ECM stiffness regulates cell behaviour [56].  
2.4. Scaffold Architecture 
The tissue framework demands an interconnected pore network and high porosity 
to guarantee cell proliferation and continuous flow of the medium. The network provides 
nutrients, gas exchange and an elimination route of cellular waste and scaffold degrada-
tion by-products [24]. As such, the architecture and porosity of the matrix must be finely 
balanced to ensure the facilitation of protein exchange between cells through the intercon-
nected pores, without, however, compromising the mechanical integrity and stability [58].  
The mean pore size and surface area of the scaffold are intrinsically connected to the 
ligand density. Therefore, an optimal scaffold architecture not only entails large pore sizes 
for cell migration but, at the same time, small enough pores that an adequate high specific 
area surface is available with a low ligand density [59,60].  
For example, in 2016, the effect of different pore sizes and porosity on a chondrocyte 
seeded scaffold was studied by analysing cell proliferation, viability and cell-specific cre-
ation of cartilaginous ECM. The results demonstrate that cell density increased up to 50% 
with an increase of pore size and porosity associated with bigger surface area for migra-
tion and mass gas/nutrients exchange within the scaffold. Moreover, the production of 
GAG (glycosaminoglycan) and collagen-specific constituents also increases 
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proportionally with pore size. Nevertheless, it was reported a decrease by 40% of meta-
bolic activity and ECM synthesises with pore size increase. These results imply that chon-
drocytes synthesise less matrix when the pore size is bigger. This study shows how im-
portant the scaffold architecture is to the behaviour of cell cultures and that different con-
siderations must be undertaken to understand what the needs for a specific cell line are 
when choosing the material/manufacturing technique to produce a scaffold [61]. 
Furthermore, surface topography is incredibly important to regulate cell fate. In vivo 
actin cytoskeleton remodelling controls the mechanical homeostasis of cells, thus it is im-
perative that this function is recapitulated in synthetic scaffolds for OOAC devices 
through the design of topographic and mechanical indications on the surface of the scaf-
fold [62]. For instance, cell alignment can be affected by altering protein adsorption. More-
over, on PLGAA scaffolds, the use of type-I collagen meditates attachment [63]. 
2.5. Manufacturing Technology 
The manufacturing technique used to create the scaffold will influence both the me-
chanical properties and architecture. It must be cost-effective and permit scale up to batch 
fabrication for the research industry [24]. Scientific advances have allowed the creation of 
manufacturing technologies such as electrospinning [26], 3D printing [64] and injection 
moulding [65], among others, which enable the fabrication of complex constructs. Fabri-
cation standards must be established to guarantee the different scaffolds can be used for 
pre-clinical OOAC system testing [35]. 
2.6. Scaffold Integration in OOAC System 
OOAC systems have a chamber that is fed by an inlet for media and an outlet for 
media waste. The chamber not only plays the role of housing the scaffold and tissue but 
is also engineered to mimic mechanical cues if necessary. For example, the chamber of the 
Lung-on-a-Chip undergoes cyclic mechanical stretching through vacuum manipulation 
to recapitulate breathing movements [66]. 
The integration of the scaffold within the chamber is crucial for the functioning of the 
chip as a pre-clinical model. The type of scaffold being used—hydrogels or stiffer materi-
als for scaffolding—must be taken into consideration when designing the chip system and 
will dictate how it can be applied to the system [67]. 
2.6.1. Hydrogels 
Hydrogels are 3D polymer frameworks that contain high volumes of water [68]. 
These materials are permeable due to the affinity of the polymer to a solvent’s molecule 
[69]. OOAC devices are micro-scaled, which means methodologies must be adapted to 
accommodate the filling of the device with this type of scaffold. Approaches vary between 
fabricating a scaffold with hollow channels or creating channels from the material itself 
[70,71].  
Virumbrales-Muñoz et al. used a microfluidic device to study the capability of TNF-
related apoptosis-inducing ligand (Trail) to kill tumour cells by using Collagen scaffold-
ing. The hydrogel was placed on top of the inlet and polymerised at 37 °C, followed by 
culturing of endothelial cells [72]. This is one of the many examples where a hydrogel is 
delivered to fill a channel or chamber through an inlet and held in place by the surface 
tension, which undergoes subsequent curing. Nevertheless, this simple method comes 
with limitations such as the lack of cell alignment [73] and the lateral flow, which feeds 
the cells might be insufficient depending on the thickness of the scaffold since hydrogels 
thicker than 200 µm can lead to cell necrosis from the lack of oxygen delivery [74].  
Another method is the fabrication of microchannels in hydrogel parts, as referred to 
above. A master mould created using photolithography, sacrificial or physically remova-
ble moulds are frequently used to create microfluidics within the chosen hydrogel [75]. 
This is a straightforward technique referred to as replica moulding. Nevertheless, it still 
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presents challenges such as the use of stiffer materials that, to structural integrity, affect 
the viability of cellular encapsulation since they have high material density. Moreover, 
deformation of the created microstructures in soft gels has been reported [67]. Bioplotting 
has been vastly used due to its ability to create 3D structures with a specific design [76]. 
Both bioplotting and replica moulding techniques can be used to create microfluidic de-
vices from hydrogels [67].  
2.6.2. Additive Manufacturing Derived Scaffolding 
Additive manufacturing derived scaffolds such as electrospun and 3D printed scaf-
folds require different approaches concerning their integration within an OOAC system. 
Static systems protocols include the peeling of the membrane from the collector, cutting it 
to the desired shape, followed by the placement of this membrane in the culturing cham-
ber after proper sterilisation. Nonetheless, the simplicity of this procedure derives from 
the lack of shear stress, waste removal and gradient control characteristic of OOAC sys-
tems [67]. 
Different methods have been developed to introduce scaffolds into microfluidic 
chips. One of these methods is the lateral flow model used by Pimentel et al. where certain 
areas of the membrane are occluded to create a hydrophobic zone around the channels 
[77]. The disadvantage of this method is that it is not appropriate for cell lines that need 
shear stress [67]. 
Another method of integration of the scaffolds into the OOAC was developed in 2016 
by Chen et al., which was denominated by dynamic focusing electrospinning technology, 
which enables the spinning of a scaffold directly onto the fluidic chamber. This method 
enables the introduction of flow through the tissue but requires a channel wider than 1 
mm [78]. 
Modular integration of the manufactured scaffold in the microfluidic system was re-
ported by Chen et al. in 2018, where the membranes are cut into the dimensions of a spe-
cific chip. Cells are then seeded onto the scaffold and then inserted onto the microfluidic 
chamber, followed by the introduction of flow to the system [79]. This method presents 
advantages such as the ability to remove the cellular cultured inserts, for example, in case 
of contamination or for imaging, from the system itself [67]. 
3. Biomaterials 
The chemical composition of different materials—both naturally derived and syn-
thetic polymers—plays a vital role in the enhancement of the scaffold’s properties men-
tioned in the previous section, which are critical for the growth of cells in the manufac-
tured scaffolds [35].  
3.1. Naturally-Derived Materials 
Natural polymers are obtained from nature—plants, animals, insects and even hu-
mans. These materials provide reliable scaffolds since their mechanical and chemical 
properties are identical to those in the natural tissues that we aim to replicate, allowing 
cells to easily proliferate and differentiate in the OOAC system [35]. 
3.1.1. Matrigel 
MatrigelTM has been widely used in the Tissue Engineering field for the past 40 years. 
This basement-membrane matrix is extracted from the Engekbreth-Holm-Swarm mouse’s 
sarcoma, which produces large amounts of ECM [80]. It is one of the most sought-after 
animal-derived materials for the development of three-dimensional cell cultures since it 
provides a gel-like scaffold that enables cells to form more complex and accurate struc-
tures than two-dimension planar cell cultures [15]. It promotes cell adherence due to its 
primary composition of over 1000 ECM proteins [81], including—laminin (~60%), type IV 
collagen (~30%), entactin (~8%) and the heparin sulphate proteoglycan perlecan (~2–3%) 
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[80]. These proteins allow for the existence of microenvironments of soluble growth fac-
tors—transforming growth factor (TGF) family peptides (for example, TGFβ) and fibro-
blast growth factors (FGFs) [81]—along with hormones among other major molecules [16].  
One successful example of the use of MatrigelTM in OOAC platforms is the Liver-on-
a-Chip system. The Liver-on-a-Chip system was developed as a method to increase the 
prediction rate of Drug-Induced Liver Injury. The membrane is deposited in between two 
cell layers [10]. Three-dimensional cultures within MatrigelTM have been proven to be sig-
nificantly more sensitive to drugs rather than two-dimensional cultures and present cel-
lular structures that closely resemble the in vivo tissue [82]. Moreover, MatrigelTM has 
been embedded with hepatocytes on a microfluidic chip by Jang et al. since it maintains 
cellular morphology by preventing cellular differentiation and polarization [83]. 
Nonetheless, the use of MatrigelTM has been shown to be restrictive by several prote-
omic analysis studies due to the batch-to-batch composition variability. Some factors re-
sponsible for this variability include protein and endotoxin concentrations [84] that can 
impact the formation of 3D structures, as well as the presence of numerous growth factors 
that can affect immunoassays [81] Further, the existence of xenobiotic contaminants, 
which act as confounding factors, lead to confounding results and an inconclusive under-
standing of which signals promote cells functioning [85].  
Consequentially, the composition inconsistency alters the mechanical properties be-
tween batches. For example, Young’s modulus, has been shown to be low at <0.2 kPa [86–
88]. Furthermore, the animal-derived nature of MatrigelTM can influence cellular behav-
iour [89].  
Therefore, there is a need to replace MatrigelTM with a material that can recreate a 
three-dimensional environment whilst still allowing cell adherence, cell signalling and 
mechanical cues, that do not have a variable batch to batch protein composition [16].  
3.1.2. Collagen 
One of the most predominant proteins in the ECM is collagen since it accounts for 
approximately 30% of the proteins within a mammal [90]. Its fibrillar structure contributes 
to the extracellular scaffolding of natural tissue, maintaining the structural integrity of the 
tissue [91]. Not only does collagen control morphology, adhesion and differentiation of 
the cells, but it has also been found to have low immunogenicity, good biocompatibility, 
porous structure leading to good permeability [92], and it is more biodegradable when 
compared to other scaffolds [93].  
Collagen can be extracted from different species, including rat, bovine, porcine and 
fish, among others, and its origin influences the solubility of the scaffold structure [94,95]. 
This scaffold has been used for decades to regenerate damaged tissue; however, its use in 
3D culture has increased in recent years due to its tunable properties [96]. The human 
colon has a Young’s modulus of E = 0.63 ± 1.25 MPa [97].  
The Gut-on-a-Chip incorporates a collagen scaffold to emulate the shape and density 
of human intestinal villi. This hydrogel scaffold was chosen because it allows to closely 
emulate the native ECM microenvironment of the gut, inducing cell differentiation while 
maintaining integrity and barrier function. This scaffold is seeded with Caco-2 cells and 
results in a uniform monolayer across the surface of the villi [98]. The system was devel-
oped as a solution to the limitations of 2D in vitro models, with the goal of understanding 
the complex process of absorption and metabolism of drugs in vivo [99]. It has proven 
difficult for scientists to acquire accurate results for Young’s modulus of collagen with a 
range from 0.13–9.1 kPa [88,100].  
Nonetheless, collagen manufactured scaffolds lack mechanical strength and struc-
tural stability when hydrated, which limits their application. To overcome this limitation, 
collagen scaffolds are often mixed with other materials, or intermolecular cross-linking 
can be used to improve the mechanical stability of the structure. Moreover, further bio-
chemical factors can be included in the scaffold to enhance cellular response [101]. The 
polymerization reaction is dependent on temperature, pH, ion chemistry and monomer 
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concentration, which affects its inherent properties. For example, increasing the pH value 
results in decreased fibre diameter and pore size and stiffer gel matrix [102].  
3.1.3. Chitosan 
Chitosan is the second most common amino polysaccharide that is obtained as a 
deacetylated derivate of chitin. Chitin is found abundantly in the exoskeleton of crusta-
ceans and insects [103]. Chitosan has a similar structure to glycosaminoglycans and has 
been used in the pharmaceutical industry since the early 1990s owing to its immense ben-
eficial properties such as biocompatibility, biodegradability, antibacterial and antifungal 
activity; it is a polycationic polymer and shows permeation enhancement [104]. Chitosan 
hydrogels have a low interfacial tension with water and biological fluids [105] and the 
capability to absorb water without compromising structural stability. The mechanical 
properties of this biomaterial are dependent on the charge and degree of crosslinking. For 
example, enhancing the crosslinking leads to increased stiffness and Young’s modulus 
[106]. Its crystalline nature allows it to be processed using different methods to create dif-
ferent scaffolds types, including gels, nanofibres and sponges [107]. Moreover, chitosan 
membranes can be responsive to light, pH, temperature and ionic concentration [108].  
For example, collagen-chitosan hydrogels were used by Chiu. et al. as scaffolds for 
the vascular OOAC system to achieve angiogenesis with endothelial cell proliferation. The 
positively charged nature of the chitosan was used to induce the sustained release of neg-
atively charged encapsulated Tβ4, which is a protein that is used to increase cell density 
in scaffolds in this specific system. [109]. 
Nevertheless, chitosan and chitin scaffolds have limitations as mechanical tests have 
shown them to be mechanically weak and unstable. These vary according to chitosan 
weight percentage, gelation method and degree of acetylation; one study showed results 
from 5–2500 kPa [110] by altering these factors. Hence, polymeric blends are used to en-
hance these properties [107]. 
3.1.4. Alginate 
Alginate or alginic acid is an anionic polysaccharide found in brown algae. The pro-
duction cost of this polymer is reduced by marine extraction from algae, and it can also 
be synthesised through microbial fermentation [111]. Mechanical and chemical properties 
of alginate may vary according to the seasonal growth conditions of the source [112]. Al-
gae derivates have abundant G blocks content, while bacterial derivates possess high con-
centrations of M blocks content. Currently, there are more than 200 alginates being pro-
duced [113]. It has been considered biocompatible with human tissues both in vitro and 
in vivo. However, the purity of alginate can impact this factor [114].  
Alginate nanofibres have shown good potential as a tissue engineering scaffold for 
skin, bone, cartilage, and liver cell types. Nevertheless, the manufacturing of these scaf-
folds is still associated with many challenges, such as successful electrospinning of pure 
alginate nanofibres due to the strong inter and intramolecular hydrogen bonding between 
the stiff molecular chains [115]. Hence, composites with other polymers or cross-linking 
methods are created to improve the ability to be electrospun [116].  
The viscosity of alginate solutions increases with the decrease of the pH, reaching its 
maximum viscosity at a pH ranging between 3–3.5. The molecular weight of commercially 
sold alginate is between 32,000–40,000 g/mol [117]. Altering the molecular weight of the 
solution can improve the mechanical properties of the hydrogel [118]. Without additives, 
the hydrogel has been shown to have a Young’s modulus of 0.2–1.3 kPa whilst later stud-
ies have shown higher values up to 6 kPa as the weight percentage of alginate is increased 
[88,119]. Alginate is not naturally degradable in mammals as they lack the enzymes to 
cleave the polymer. Hence, the polymer can be cross-linked with divalent ions to increase 
its solubility [117]. Moreover, alginate lacks the ability to bind to mammal cells, which is 
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vital for the regulation of cellular interactions between scaffold and tissue. Consequently, 
peptides such as RGD are used as adhesion ligands to increase cell viability [120]. 
Alginate membranes have been used in microfluidic devices with different cell types 
(cardiac tissue, liver, and hepatocyte spheroids) for cell encapsulation [121] as sacrificial 
material for vascular network patterning [122] and for drug testing models [123]. This 
scaffold has been reported to emulate the 3D ECM of many soft tissues both chemically 
and physically. However, this material still presents its challenges when it comes to using 
it on microfluidic devices, such as its flexibility and controllable formation [121]. Besides, 
studies have reported poor cell attachment to alginate scaffolds because of the inability of 
human cells to attach to negatively charged surfaces [123]. 
3.1.5. Cellulose 
Cellulose is the β-(1→4)-linked polymer of D-glucose that has a structural role as a 
load-bearing element in the cellular wall of plants. It is the most common naturally de-
rived molecule in the environment [124]. Cellulose type I is the crystalline form of natural 
cellulose and has two existing polymorph forms with different origins—cellulose Iα and 
cellulose Iβ. Cellulose Iα is a single chain triclinic unit mostly present in bacteria-derived 
cellulose. On the other hand, cellulose Iβ has a double chain monoclinic structure, which 
can be retrieved for instance, from cotton and wood [125]. The microfibrils range from 10–
30 µm depending on the cellulose sources [126].  
Bacterial cellulose (BC) derived from Acetobacter xylinum is abundantly used in the 
pharmaceutical industry as a scaffold. It is insoluble in water and is degraded by microbial 
and fungal enzymatic activity [127]. Cellulose nanofibrils create a network with high me-
chanical strength, a high level of water retention [128] and show high hydrophilicity, 
which is optimal for cellular growth and proliferation in three-dimensional scaffolds 
[127]. BC network densities are tunable biomaterials that can be modified by varying the 
cell culture conditions [129]. The Young’s modulus in air-dried BC sheets has been shown 
to be as high as 16.9 GPa, with an elongation of 1.7% and tensile strength of 256 MPa [130].  
Cellulose nanofibres are transparent, which is beneficial for microscopy analysis of 
cell morphology throughout the experiment [131].  
Shin et al. developed a microfluidic platform that used a cellulose nanofibre to un-
derstand the role of cisplatin in the death of lung cancer cells and test the lethal dose of 
anticancer drugs; this in vitro model was proven to be effective in the study of cell behav-
iour, cell–cell interactions and chemical toxicity [132].  
3.1.6. Gelatin 
Gelatin is obtained by hydrolyzing and denaturing animal skin [133]. Its origin 
makes it extremely biocompatible, biodegradable and non-immunogenic. It has good wa-
ter-solubility and is readily available from commercial sources for the emulation of human 
tissue [134]. Whilst gelatin composition is similar to collagen, it is a lower cost polymer 
and less antigenic [135].  
Gelatin has been one of the most promising polymer scaffolds because of its biodeg-
radability [136]. The source of the gelatin and the conditions in which it is extracted dictate 
the molecular structure and physical properties of the polymer. The Bloom Index is used 
as a measure of gel strength for gelatin. The Bloom index has higher values when gelatin 
extraction occurs at lower temperatures making the hydrogel stiffer [137]. The defor-
mation and stress at break increase with the increase of the Bloom Index, consequently, 
Young’s modulus increases linearly with this parameter [136].  
Gelatin hydrogels have been used as a tunable scaffold to emulate the cardiac tissues 
ECM (Young’s modulus ranging from 10–15 kPa [138]) due to a similar Young’s modulus, 
that is similar elastic properties when undergoing tension or compression in one direction. 
These showed higher spare respiratory rates with an improved metabolic function when 
compared with fibronectin-coated PDMS scaffolds [139]. Moreover, vascular chips were 
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successfully developed with gelatin methacrylate (GelMA) as a vascular model since it is 
a denatured derivate from the most common protein in the body and contains RGD. It is 
semi-transparent, allowing UV crosslinking. This study demonstrated that this material 
lined with HUVECs creates a good barrier function. [140]. GelMA has also been used be-
cause of its biocompatibility and low viscosity as a scaffold for a muscle model [141]. 
3.2. Synthetically Derived Materials 
To create low-cost enhanced scaffolds, new approaches have been taken by research-
ers to create new synthetic materials that could replace naturally derived biomaterials 
without compromising their key requirements.  
3.2.1. Poly-(Ɛ-caprolactone)—PCL 
Poly-(Ɛ-caprolactone) is a linear synthetic biodegradable polyester, which can be ac-
quired at a low cost, and is extremely versatile for scaffold development [142]. This ali-
phatic polymer has been approved by the Food and Drug Administration (FDA) for bio-
medical and tissue engineering applications due to its ideal mechanical and biological 
properties. Biodegradable polyesters are frequently used in scaffold manufacture: these 
include PCL and poly-L-lactide [143]. 
The biodegradability of PCL has been tested and shows large variation dependent 
on specific parameters, including material properties, scaffold architecture and environ-
mental conditions. Microorganisms have been shown to accelerate the degradation of PCL 
scaffolds [144]. Nevertheless, hydrolytic cellular mechanisms have since been proven to 
cause slow degradation of PCL when compared with naturally-derived polymers 
[145,146]. 
PCL is a hydrophobic material that is problematic for cellular adherence and interac-
tion [147]. Thus, to functionalise its surface, it is frequently blended with amino acids se-
quences (RGD, GRGDSP, PSHRN and IKVAV) and peptides such as fibrin [142]. PCL 
tends to be used as a copolymer as it has stable mechanical properties that can enhance 
the stability of naturally-derived materials whilst increasing hydrophilicity, cell adher-
ence and viability [148]. The average molecular weight of PCL ranges from 530 to 630,000 
Mn/g mol−1 [142]. PCL is soluble in most organic solvents such as chloroform, cyclohex-
anone and 2-nitropropane at room temperature [149]. Scaffolds of bulk PCL have a tensile 
strength between 25–43 MPa and a Young’s modulus ranging from 330–360 MPa; porous 
and fibrous scaffolds have lower tensile strength and Young’s modulus dependent upon 
scaffold architecture [150].  
PCL/Polydopamine (PDA) scaffolds have been used to emulate the myocardium in 
a muscle-inspired microfluidic system aimed at measuring cardiac contractility. The scaf-
folds resulted in a framework that gave topographical signalling for the formation of ani-
sotropic cardiac tissue [151]. A porous PCL/poly(lactic-co-glycolic acid)—PLGA—micro-
fluidic perfusion membrane was developed to replicate the vasculature network. This 
scaffold has been used for co-culture of endothelial cells, pericytes, astrocytes and neural 
stem cells in an ex vivo blood-brain barrier model, with high mechanical strength, bio-
compatibility and biodegradability [152]. Furthermore, PCL scaffolds coated with colla-
gen gel were used to investigate the cell-cell and cell-ECM interactions in endothelial cells 
monolayers lining with the purpose of further understanding vascular diseases and can-
cer metastasis [153]. 
3.2.2. Poly-(dimethyl-siloxane)—PDMS  
Poly-(dimethyl-siloxane) or PDMS is the most widely used silicon-based organic pol-
ymer for both the manufacture of microfluidic chips and scaffolds due to its elastomeric 
properties, cell biocompatibility, gas exchange and optical transparency [7]. 
PDMS came to the forefront of OOAC systems due to its abundant use in Lab-on-a-
Chip systems—an area of analytical science that proceeded OOAC. PDMS was used 
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primarily within academic research due to its low cost and ease of manufacturing using 
soft lithographic methods [154]. It is optically transparent, which allows real-time analysis 
of cell cultures without having to destroy the OOAC system; however, it is hydrophobic, 
which poses a disadvantage for cell adhesion [155]. It is extremely flexible due to its low 
glass transition temperature (Tg −125 °C) [156].  
PDMS is known to adsorb small molecules and drugs, which can either be an ad-
vantage or disadvantage depending on the chosen application [157]. The Si-O- bond in 
PDMS is responsible for its thermal and chemical stability [158]. 
PDMS scaffolds produced by Si, J. et al. have a compressive modulus of 19.69 ± 1.42 
kPa and compressive strength of 4.76 ± 0.22 kPa due to its high porosity [159]. The stiffness 
of the membranes varies according to the type of cell that is cultured and the formation of 
their focal points [160]. Even though PDMS is largely used as a scaffold for the OOAC 
systems, it possesses a vital disadvantage, it is not biodegradable, which means it cannot 
be replaced by natural cell-produced ECM [161]. Moreover, lasting submersion in organic 
solvents leads to swelling and detachment of the produced layers affecting the surface of 
the membrane [162]. PDMS is often coated with ECM proteins to increase cell attachment. 
However, the bond between both can be degraded when exposed to sufficient shear stress 
from the flow in OOAC systems [163]. The Lung-on-a-Chip takes advantage of the PDMS 
flexibility to emulate the cyclic loading lung tissue is subjected to. A thin (10 µm) porous 
PDMS membrane was coated with fibronectin or collagen, human alveolar epithelial cells, 
and human pulmonary microvascular endothelial cells [164]. 
In 2018, Quirós-Solano et al. reported cell migration and healthy growth of cells in 
the porous membranes with HUVEC and MDA cells while using this polymer as a spin-
coated scaffold [162]. 
A Kidney-on-a-Chip device has also been created using PDMS membranes to test the 
drug metabolism process that influences renal adverse effects. Liver slices were cultured 
between a polycarbonate and PDMS membrane [165]. Moreover, PDMS membranes 
coated with ECM were seeded with Caco-2 intestinal epithelial cells to emulate a human 
Gut-on-a-Chip model [13]. 
3.2.3. Polylactic Acid—PLA 
Polylactic acid is a biodegradable polymer firstly synthesised in 1780 and is acquired 
from the chemical synthesis of acetaldehyde and carbohydrate fermentation process [166]. 
PLA’s molecular weight distribution impacts the mechanical, biological and degradation 
rate [167]. This parameter can be modified by azeotropic distillation and a longer polymer-
ization time [168]. PLA can be dissolved in various solvents, including dioxane, tetrahy-
drofuran and hot benzene [169]. It is a thermoplastic material that can be manufactured 
into fibres and films. The mechanical properties vary according to the scaffold manufac-
turing technique used [170].  
PLA can be degraded when its ester bond is exposed to hydrolysis and the degrada-
tion rate is dependent on the isomer ratio, temperature of the reaction and structure and 
size of the scaffold [171].  
PLA has numerous distinctive forms, such as poly-L-lactide (PLLA) and poly-D-lac-
tide (PDLA) since lactic acid has chiral nature. This allows the stereochemical structure to 
be modified in order to change its mechanical and chemical properties [169]. 
Cell culture chips have been prepared with PLA exhibiting different surface topolo-
gies with the aim of housing human mesenchymal stem cells (MSCs) and studying the 
phenotypic differentiation they undergo. It was shown that smaller and higher density 
pores on the surface of PLA induced pluripotency of human MSC. PLA membranes that 
are exposed to mechanical strain are not recommended due to their high Young’s modu-
lus, membranes that incorporate PEG to act as a plasticiser, and lower Young’s modulus 
still show high values with E = 5–7 MPa [49,172]. 
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3.2.4. Polyethhene Glycol—PEG  
Polyethene Glycol or PEG hydrogels are highly biocompatible with natural tissue, 
and their mechanical properties can easily be manipulated by adjusting weight percent-
age, molecular chain length and cross-linking density. Cross-linked PEG forms a porous 
hydrogel that closely emulates the ECM of human tissues [173]. The liquid-to-solid tran-
sition for the gelation process can be easily controlled in the presence of cell suspensions 
[174]. It is an inexpensive scaffold derived from the living anionic ring-opening polymer-
ization of ethylene oxide, and its molecular weight ranges from 0.4–100 kDa, and it is sol-
uble in water [175]. Circulation of small molecules has been reported to be extended with-
out compromising the bioactivity of PEG attached through covalent or noncovalent inter-
action [176]. Furthermore, PEG is hydrophilic and inert, presents low protein absorption, 
which is important for the cross-linking and ligands presentation to cells [177]. The poly-
mer concentration, chain length and configuration have been discovered to play a role in 
the mechanical and chemical properties of PEG, which can easily be engineered in accord-
ance with the tissue to be replicated [178]. Young’s modulus for PEGDA was found to 
vary from 0.5–1.9 kPa for concentrations of 5–20% (weight:volume), respectively, whilst 
values up to 700 kPa have been seen by using low molecular weight PEG [88]. 
PEG hydrogels are FDA-approved and have been vastly used in regenerative medi-
cine as a delivery strategy and as a scaffold. PEG flexibility can be manipulated when 
using different functional groups and mixed polymerization techniques [177]. However, 
it is commonly used in combination with other biopolymers, such as hyaluronic acid, fi-
brinogen, chitosan and heparin with to enhance the scaffold’s properties [178].  
3.2.5. Polyglycolic Acid—PGA  
Polyglycolic Acid (PGA) is an FDA-approved linear aliphatic polyester, which is non-
toxic and does not induce immunogenicity, it is biodegradable and biocompatible [179]. 
PGA can be derived from natural resources such as rice, wheat and sweet potato via the 
process of fermentation and polymerization [180], which makes it an alternative to ani-
mal-derived scaffolds. These scaffolds are vastly used because of their tunable degrada-
tion rate and easy processing [181]. PGA is a thermoplastic; thus, it can be easily manu-
factured in accordance with tissue specifications [182]. Its degradation occurs by non-en-
zymatic hydrolysis, which results in non-toxic metabolites. PGA has a tensile strength of 
57 MPa and a Young’s modulus from 6–7 GPa [183]. Nonetheless, PGA and its copoly-
mers, including poly(lactide-co-glycolide) or PLGA—disintegrate relatively fast since 
their tensile strength decays to half within two weeks [184]. Consequently, like many 
other polymers, it has been modified to enhance its properties. For example, the use of 
polyurethane coating has been proven to enhance cell adhesion, growth, and proliferation 
in PGA scaffolds [185].  
These scaffolds were successfully used for the culture of autologous smooth muscle 
and urothelium, which effectively emulated the function of bladder tissue [186], which 
makes it a viable option to reproduce similar smooth tissue within OOAC systems.  
3.2.6. Polyurethane—PU  
Polyurethane scaffolds have gained increasing interest for biomedical applications 
since they are biocompatible and have advantageous mechanical properties [187]. These 
synthetic polymers have a distinctive segmented structure, which allows the manipula-
tion of a wide range of properties. The composition and manufacture of the polymer will 
affect properties such as hydrophilicity and the degradation rate [188].  
This biomaterial can be manufacturing using a variety of techniques, which allows a 
customised production according to the scaffold aim [187].  
TPU has been recently used as a scaffold for a Lung-on-a-Chip system due to its bio-
compatibility, flexibility emulating the mechanical stretching of the in vivo membrane and 
optical clarity, which easily allows observation and collection of qualitative data. Thus, 
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this material can be used successfully as a biocompatible and versatile scaffold for the 
growth of complex cellular constructs within OOAC devices, specifically those that re-
quired mechanical cues such as cyclic stretching [189]. Novel biodegradable PU elasto-
mers have been developed to act as scaffolds for soft tissues. These incorporate PEG and 
poly(δ-valerolactone-co-ε-caprolactone) and have shown E = 600 ± 140 kPa [190]. 
3.3. Materials Overview 
Table 1 below contains an overview of the materials’ advantages and disadvantages 
according to the literature described in Section 3 of the paper. 
Table 1. Materials overview. 
Material Advantages Disadvantages Examples of OOAC  References 
Matrigel 
Promotes cell adherence. 
Extremely biocompatible. 
Similar mechanical proper-
ties as natural ECM. 
Batch to batch composition 






Most predominant protein 
in mammals’ ECM. 
Controls morphology, ad-
hesion, and differentiation. 
Good permeability. 
Lacks mechanical strength 
















Reduced production cost. 
Mechanical Strength can be 
adjusted depending on mo-
lecular weight. 
Purity will affect biocom-
patibility. 
It will not naturally de-
grade in mammal derived 
tissues. 
Poor cell adhesion. 
Microfluidic devices us-





Insoluble in water. 
High mechanical strength. 
Allows water retention. 
Biocompatible. 
Optical transparent. 
Degraded by microbial and 
fungal enzymatic activity. 
Microfluidic device using 





















Slow biodegradability rate. 
Microfluidic devices to 








High flexibility adequate 
for cyclic stretching. 
Non-degradable. 
Hydrophobic. 










Mechanical properties are 
tunable. 
Not suitable for OOAC sys-
tems with high mechanical 
strain. 







High degradation rate. 
3D cultures of autologous 








High Mechanical Strength. 











Compatible with many 
manufacturing techniques. 
 Lung-on-a-Chip [187–189] 
4. Manufacturing Techniques 
Manufacturing techniques for tissue engineering scaffold production have been de-
veloped and optimised for decades. The different characteristics of each of these are vital 
to produce scaffolds with different mechanical and chemical properties and, alongside 
material properties, add to their versatility.  
Pore size, fibre diameter and architecture are some of the properties that are tunable 
depending on the technique of manufacture chosen. These play a vital role in the cell via-
bility of different tissues because of the different mechanical requirements for each cell 
line whilst providing structural integrity and support for the cells and their ECM. Table 2 
gives an overview of manufacturing techniques, materials used, pore size range, and a 
brief overview of the advantages and disadvantages of each method (Section 4.6). 
When choosing a suitable manufacturing method pore size and the amount of poros-
ity are important. Pore size will depend on the size of cell type under investigation, po-
rosity is an important factor to consider as it will allow cell media to reach cells embedded 
in the membrane and cell signalling factors including cytokines, chemokines and growth 
factors along with nutrient exchange to take place. The pore size chosen will depend on 
the final use of the device and tissue under investigation; for example, trophoblasts were 
successfully cultured on two matrices with a pore size of 30 and 39 µm with optimal pro-
liferation seen on the 30 µm membrane. However, fibroblasts have been seen to proliferate 
on membranes with greater pore size, 100–150 µm depending on porosity [194,195]. The 
pore size and porosity will further affect the mechanical properties of the materials, too 
high a porosity and the scaffold will become mechanically unstable. This must be taken 
into consideration when designing a scaffold for OOAC applications. 
 
   
(a) (b) (c) 





(d) (e) (f) 
  
(g) (h) 
Figure 2. This figure includes schemes of each manufacturing technique manufacturing process. (a) Electrospinning 
Scheme—Section 4.1; (b) stereolithography or SLA scheme—Section 4.2.1; (c) fused deposition modelling or FDM 
scheme—Section 4.2.2; (d) selective laser sintering or SLS scheme—Section 4.2.3; (e) bioplotting scheme—Section 4.2.4; (f) 
salt leaching scheme—Section 4.3; (g) phase separation scheme—Section 4.4; (h) freeze drying—Section 4.5. 
4.1. Electrospinning 
Electrospinning is a common method used to manufacture nanofibre scaffolds [196]. 
This technique consists of the application of a high voltage to produce an electric field 
between the needle tip, from which a polymer solution is dispensed and the ground plate 
where fibres are collected (Figure 2a). The applied voltage induces a charge within the 
polymeric solution [197]. Once the electrical charges overcome the surface tension of the 
fluid, a Taylor cone is formed, and a polymeric jet is expelled from the spinneret of the 
capillary. The solution droplets will be drawn towards the collector plate as it does not go 
through Rayleigh volatilities [198]. With an increased surface charge density, the fluid jet 
will turn into fibres as it approaches the collector, producing a mesh of fibres. The diam-
eter of the electrospun product can be controlled by altering the flow rate of the syringe 
pump, the concentration of the fluid, and the distance between the needle tip and the 
collector [199]. The increasing diameter of the fibres is associated with the increased aver-
age pore size of the scaffold [200]. The high surface area and high porosity inherent to 
electrospun membranes are beneficial for cell attachment and waste exchange [22]. Elec-
trospinning usually creates a nonwoven fibrous mesh with a pore size from around 3–5 
μm. However, it can be manipulated by the fibre orientation and polymer chosen [201].  
This technique is straightforward and inexpensive and can be used with a wide va-
riety of polymers to produce viable scaffolds (Table 2). Nevertheless, the polymer must 
be turned into a solution to allow the electrospinning process, and this requires the use of 
toxic organic solvents during the manufacturing process, which can be cytotoxic and im-
pact cellular viability [202]. Moreover, the fibres spin randomly, making it hard to control 
the pore size and structure [203]. Some examples of scaffold materials used in this manu-
facturing technique are available in Table 2 (Section 4.6). 
This technique has been incorporated to create an electrospun PLGA membrane into 
a Lung-on-a-Chip developed by Yang et al. The membrane was used for co-culture of lung 
cancer derived epithelial cell, lung fibroblasts and human umbilical vein endothelial cells 
[192]; the group show a facile sealing method and thus ease of integration into an OOAC 
system. Chen et al. have developed a novel method to electrospin PCL fibres directly into 
3D printed microfluidic channels to culture fibroblasts with a pore size of 113 ± 19 μm 
showing the diversity of the technique [78]. 
4.2. Three-Dimensional (3D) Printing 
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There are numerous methods of 3D printing, some involving the deposition of layers, 
others the solidification of polymers. The shape of the model is predetermined and de-
signed by computer-aided design (CAD) software, together with a slicer software and 
material choice allows the control of pore size, porosity and architecture [204]. An over-
view of each 3D Printing technique is available in Table 2 (Section 4.6), along with some 
material examples and pore size dimensions. 
4.2.1. Stereolithography (SLA) 
Stereolithography is a 3D printing technique that uses an ultraviolet (UV) LASER to 
cure an individual layer within a vat of UV curable photopolymer resin (Figure 2b) to 
create the scaffold [205].  
CAD files define the accurate pattern that the UV laser will irradiate. Free radicals 
are produced upon the excitation of photoinitiator molecules of the UV, which leads to 
the polymerization of the polymeric scaffold layer. The first layer is used as an adherence 
platform, which offers support to the scaffold structure. After the process is completed, 
the model is cured in an oven [206]. This technique allows the production of an array of 
shapes using different polymers. The resolution of the architecture is dependent on the 
spot size of the chosen laser and of the elevator layer [22]. Nonetheless, the additional 
curing necessary to improve the scaffold properties compromise the resolution due to the 
shrinkage that may occur during postprocessing. Further, there is a limited amount of 
materials that can polymerise under UV [207]. The benefit of stereolithography over tech-
niques such as electrospinning is that the final scaffold is well defined with known pore 
size. 
Stereolithography has been used in macro tissue engineering, often for bone regen-
eration, and this can be translated to OOAC technologies looking for similar mechanical 
properties. Techniques including ceramic stereolithography have become available and 
used to understand optimal pore size for osteogenesis [208]. SLA has a porosity of 25–100 
μm [209]. Being one of the most accurate and with the ability to produce small pore sizes, 
this could be a useful manufacturing technique for the OOAC field. 
4.2.2. Fused Deposition Modelling (FDM) 
Fused deposition modelling is a cost-effective and fast technique to produce porous 
scaffolds [210] with a honeycomb-like structure that creates an interconnected network of 
channels required for cell and media perfusion [211].  
A thermoplastic polymer filament is melted above its glass transition temperature by 
a small temperature extruder and printed layer by layer (Figure 2c) [22]. This method al-
lows the manipulation of the porosity and structure pattern [212]. Much like the other 
rapid prototyping methods, FDM requires elevated temperatures, which limit the materi-
als that can be used with this technique [22].  
Nonetheless, it is difficult to create scaffolds with a specific porosity and pore size 
using this technology. Corral, Bagheri, Rojo have been able to optimise the technique to 
achieve pore sizes around 100–300 μm with PCL [213]. This is a method that has been 
used successfully in macro tissue engineering and can be translated to OOAC devices with 
careful control of the deposited filament diameter and pore size. The most readily availa-
ble material is PCL, which has been mixed with a range of additives for printing scaffolds, 
including hydroxyapatite, collagen [214], PLA and carbon nanotubes [215]. Fibroblasts 
have been successfully seeded and grown on scaffolds over a four-week period [216]. 
FDM has also been successfully used in bone tissue engineering [215]. 
4.2.3. Selective Laser Sintering (SLS) 
Created in 1984 by Carl Deckard [217], selective laser sintering (SLS) has been used 
for the design and manufacture of the intricate three-dimensional microarchitecture of 
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polymeric, metallic, and ceramic scaffolds, which makes it a largely used fast technique 
[218].  
In this process, a two-dimensional powder layer is printed on top of each other and 
merged when the binder solution is printed. When the model is removed, any unbounded 
powder is left behind (Figure 2d). This technology allows the production of scaffolds with 
high resolution and accuracy and the manipulation of its architecture [219]. Moreover, the 
complex shape of the scaffold leads to a homogenous cell distribution and emulates the 
natural ECM. 3D printing scaffolds’ structures range from millimetres to nanometres. The 
technology tends to be used with materials including hydroxyapatite, calcium carbonate 
composites and chitosan [220,221]. The technique is again used in bone tissue engineering. 
One drawback is the high temperature involved in this technology, which limits the num-
ber of polymers that can be used to produce a scaffold and requires a high energy input 
[217]. Degradation of the polymer may also occur—chain scission and oxidation—due to 
exposure to the laser [222]. Pore size varies according to the design of the scaffolds, nev-
ertheless, studies recorded that PCL membranes can range from 500–800 μm [223]. 
4.2.4. Bioplotting/Bioprinting 
Emerging technology has taken the principle of 3D printing and embedded cells in 
the process [224]. It takes advantage of computer-aided tissue engineering to build intri-
cate scaffolds and even artificial 3D tissues [225]. A viscous material is ejected into a liquid 
solution with a similar density (Figure 2e), therefore, the scaffold can be plotted in a 3D 
structure without the requirement for support structures. This technology allows the use 
of a variety of different materials such as hydrogels, polymeric solutions, and bioactive 
polymers with proteins, among many others [226]. The materials have a high water con-
centration, which allows the creation of cross-linked structures throughout the covalent 
bonds, which hardens the scaffold [35]. The bioplotter has the ability to dispenses solu-
tions with live cells and the chosen polymer by precisely locating the solution layer-by-
layer in a variety of sizes and with high throughput [227].  
Historically, the bioplotting downside has been its low resolution, which is a result 
of the flexibility of the bioinks and the curing of hydrogels. Moreover, this technique 
makes cells undergo high shear stress when the bioink is extruded [67].  
This technology has allowed the fabrication of artificial blood vessels [228] and skin 
[227]. Nevertheless, this is a costly technology, thus, limiting its use within research [35]. 
It has been taken up by the OOAC community and been used to develop scaffolds for a 
Heart-on-a-Chip using endothelial cells plotted with GELMA and cross-linked using UV 
light; pore size of around 100 μm was shown [229]. Along with cardiac tissue, bioplotting 
has been used successfully to mimic blood vessels, liver and kidney on a chip [230]. 
4.3. Salt-Leaching 
Salt-leaching is a simple technique largely used for scaffold fabrication [231]. The 
mould is filled with the chosen polymer, which occupies the spaces in between the poro-
gen or salt crystals. To create the scaffold, the polymer will be hardened within the mould, 
and the porogen or salt will be washed away with a solvent, for example, water or alcohol 
(Figure 2f). This process allows the creation of pores for cell attachment [232]. Some ex-
amples of materials used with this technique are available in Table 2 (Section 4.6). 
The pore size of the scaffold can be adjusted according to the amount of porogen/salt 
and these particle diameters, respectively. Moreover, this method requires a small amount 
of polymer, which reduces material waste while fabrication, unlike other rapid prototype 
fabrication methods. Salt leaching scaffolds have a porosity up to 93% and a pore size up 
to 500 μm. The size can be adjusted by using different porogen with different sizes [233].  
The salt-leaching technique cannot control the pore shape and does not reproduce 
the interconnected channels of pores necessary for media perfusion [234]. Hence, the 
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hybridization of salt-leaching with other manufacturing technologies may provide a so-
lution to these limitations [235]. 
The technique has been used successfully in macro tissue engineering but is yet to be 
seen in OOAC applications. As the method tends to be used with hydrogels it is most 
suitable for engineering soft tissues. 
4.4. Phase Separation  
Phase separation relies on the principle that a homogeneous solution, when under 
certain conditions, turns thermodynamically unstable, resulting in phase separation thus 
that the system's free energy may be lowered [236]. A solvent is used to dissolve the cho-
sen polymer and pored within a mould, which suffers precipitously cooling till the solvent 
freezes (Figure 2g) [22]. For example, gelatin scaffolds manufactured with this technique 
have an average pore size of 100 μm [237].  
This process creates two phases, one that is polymer-rich and the other which is pol-
ymer-poor. The polymer-rich phase will solidify while the latter crystallises [187]. The 
solvent in the crystallised phase is removed, leaving a porous scaffold structure. The tech-
nique does not require the leaching step, however organic solvents used for dissolving the 
polymer prevent the addition of bioactive molecules, such as RGDs. The small pore size 
limits the cell types and tissues that can take advantage of a phase separation manufacture 
[238].  
Chen et al. have recently proposed a microporous silk fibroin membrane for OOAC 
applications, this is yet to be introduced to an OOAC system, pore size is small <2 μm 
[239]. 
4.5. Freeze Drying 
Freeze-drying was firstly used by Whang et al. to manufacture PLGA scaffolding in 
1995 [193]. This is a useful technique for the manufacture of porous hydrogels [240]. An 
organic polymeric solution is poured into a mould and quickly frozen with liquid nitrogen 
(Figure 2h). Once the polymer is freeze-dried, the pressure is decreased, and the water is 
sublimated into the air phase, which leads to a porous scaffold structure [241]. 
The porosity and the pore size can be controlled by adapting the ratio between the 
water and the chosen polymer in the solution and changing the viscosity of the mix [238]. 
Moreover, the pore architecture within the scaffold can be regulated by altering the tem-
perature during the process [242]. Pore size decreases when the freezing temperature is 
diminished. Moreover, studies have shown that the insertion of an annealing step in-
creases pore size by (40%) [243].  
The removal of the various rinsing steps necessary in other techniques makes this a 
good alternative since the solvents can be easily eliminated from the scaffold [193]. None-
theless, it is a long consuming process requiring elevated levels of energy consumption 
and the use of cytotoxic solvents used to dissolve the polymer [244]. 
Freeze drying has been used to produce scaffolds for both soft tissues, cartilage and 
bone tissue engineering at the macro scale with silk-fibroin, collagen/HA and 
PCA/PCL/HA, respectively [245–247]. It is yet to be integrated into OOAC devices.  
4.6. Manufacturing Overview 
The table below contains an overview of the manufacturing techniques, examples of 
materials used and pore sizes according to the literature described in Section 4 of the pa-
per. To date, bioplotting/bioprinting has been the most utilised novel scaffold fabrication 
technique whilst electrospun scaffolds are being more commonly integrated within sys-
tems. 
Table 2. Manufacturing Techniques overview. 












High surface area. 
High porosity. 
Simple and inexpensive so-
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Wide range of polymers. 










SLA Controlled resolution. 
Final resolution may be 
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Elevated temperature that 
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rial may occur.  
PCL 
Minimum 








High resolution for an ex-
trusion system. 
Various materials can be 














Small amount of polymer 
needed. 
Does not require large ma-
chinery. 
Low-cost. 
Interpore opening and 









Harsh chemical solvents are 
not needed. 
Lower fabrication time. 
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(e.g., ethanol or methanol)  










Freeze Drying No rinsing steps. 
Reduced heterogeneous 
freezing may occur. 




Cellular growth and tissue development are intricate processes that are dependent 
on many factors that can be challenging to control. In cultures attempting to mimic the 
structure and architecture of tissues, the scaffold must be produced as an initial temporary 
ECM for cellular support and allow cellular communication and growth while proving a 
stable structure for the tissue.  
Materials and manufacturing techniques are in permanent evolution and develop-
ment. Even though there are a plethora of components that can be used to produce scaf-
folds, current state-of-art approaches are far from achieving a scaffold that fits every tissue 
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engineering requirement. Animal-derived materials are largely used since they are like 
the human tissue ECM and possess growth factors, ECM proteins and hormones, which 
control cellular growth and tissue formation. Synthetic materials have good mechanical 
properties, such as elasticity and elastic modulus whilst showing biocompatibility with 
human cellular tissue. 
Current scaffold manufacturing technologies still face challenges that must be tack-
led. Smaller pore sizes are associated with random architecture in technologies such as 
electrospinning, salt leaching and phase separation. On the other hand, techniques that 
have a high resolution of scaffold architecture are associated with pore sizes on the mm 
scale. Salt leaching, electrospinning and phase separation techniques involve the use of 
toxic solvents to dissolve the polymer, and this can be harmful to cells. Salt leaching does 
not create a wide interconnected pore network, which would limit the flow of medium 
with fresh nutrients and the expulsion of cellular waste. To solve these challenges, re-
searchers have created hybrid polymeric scaffolds by using a combination of different 
techniques and by combining additives that increase cellular viability.  
Moreover, there is a lack of standards when it comes to the use of scaffolds for specific 
cell types, with studies using different materials, which makes it hard to compare the re-
sultant data from different research groups. Thus, it is critical to test different scaffolds 
using specific cell types that have the same requirements and analyse the data using the 
same protocols to produce a single optimal scaffold that optimally emulates in vivo mi-
croenvironment. The creation of standards for the most used cell types within the OOAC 
research is a novelty that will progress the research field. 
Various studies have combined, for example, PCL with different naturally-derived 
compounds such as gelatin, collagen, chitosan and RGD, among others, thus that the 
properties of this scaffold can be optimised for its specific purpose. PLA is another exam-
ple of a polymer that has been combined with hydroxyapatite, GE, chitosan, among oth-
ers. This has become the current practice since cells thrive on these hybrid scaffolds. Cur-
rent materials used for scaffolding in the OOAC research field consist of PDMS and PCL, 
which have little or slow degradation rates and, therefore, compete for space with the 
cellular tissue.  
Traditional techniques used to manufacture scaffolds do not allow parameters such 
as pore size and porosity to be altered once manufactured. The creation of tunable scaf-
folds is the next step in the innovation of tissue engineering membranes. Biological tissues 
are extremely dynamic, therefore, “smart” scaffolds that can adapt to the cells’ require-
ments are needed to create a suitable microenvironment for cell growth for specific tis-
sues.  
6. Conclusions 
In this paper, we reviewed the different materials and manufacturing techniques that 
could be used to produce scaffolds for the OOAC research field.  
Scaffold manufacture research and tissue engineering have been greatly improved in 
the past decade with the creation of new technologies. Nevertheless, the current materials 
and manufacturing techniques still require significant research.  
From the literature, it is evident: 
• To move from animal-derived products, further research and development using 
synthetically derived products are required to achieve the same quality and repro-
ducibility of data. The use of RGD or similar anchoring proteins increases cell viabil-
ity in the tissue, enhancing the properties of synthetic materials. 
• Manufacturing techniques can be used to manipulate scaffold properties according 
to the requirements of the specific tissue making them dynamically tunable. Com-
bining different techniques and using the right materials is the key to OOAC scaffold 
standardisation. 
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• Current OOAC systems use their version of scaffolds, which makes data hard to com-
pare across research groups. This presents a major obstacle to the use of these devices 
as pre-clinical models since they are not regulated. Hence, the creation of Standards 
approved by entities such as the European Centre for the Validation of Alternative 
Methods (ECVAM) is crucial for the approval of these systems as validated models. 
Researchers from both academia and industry in collaboration with regulators could 
use standards such as ISO/TS 21560:2020 (general requirements of tissue engineering 
medical products) as a starting point to close the gap in regulation within the OOAC 
research field. 
There is still a lot of work to be conducted to create optimal scaffolds. Overcoming 
the current scaffold limitations will lead to more reliable and reproducible OOAC data.  
As a final point, this review paper aims to provide some guidance for researchers in 
the OOAC research field by encouraging further research in the development of scaffold 
standards for specific cellular tissues that allow emulation of the in vivo environment and 
reducing the cost involved. 
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